Use of bromfenac 0.09% (Broksinak) in the complex therapy for HLA-B27-associated anterior uveitis




HLA-B27-associated anterior uveitis, uveitis, corticosteroids, bromfenac, dexamethasone, glaucoma


Background: There is still no consensus among ophthalmologists as to whether the prolonged use of topical bromfenac 0.09% is feasible in therapy for acute uveitis.

Purpose: To improve the efficacy of treatment of HLA-B27-associated anterior uveitis through the use of Broksinak (containing bromfenac 0.09%) as an addditional therapy to the complex treatment regimen.

Material and Methods: This study involved 42 patients (72 eyes) with a diagnosis of HLA-B27-associated anterior uveitis. Follow-up duration was 24 months. All patients were administered systemic methylprednisolone and methotrexate. Patients of the bromfenac group were administered Broksinak eye drops (containing bromfenac 0.09%) as an additional treatment to primary systemic therapy over the course of the follow-up. Patients of the control group were administered dexamethasone 0.1% eye drops.

Results: There was no significant difference between the groups in terms of the number of recurrent uveitis episodes (р = 0.85) and laser flare reading during recurrent episodes (р = 0.56). In most recurrent uveitis episodes, laser flare readings were within the range of 20 to 50 ph/ms. There was a significant difference between the groups in the number of eyes that developed complications such as cataract (р = 0.05) and elevated intraocular pressure (р = 0.07). Cataract developed in 8 eyes of the bromfenac group and 19 eyes of the control group. At the final follow-up, elevated IOP was seen in 1 patient (1 eye) in the former group and 6 patients (7 eyes) in the latter group. At baseline, mean visual acuity (standard deviation (SD)) was 0.86 (0.21) for the bromfenac group and 0.78 (0.18) for the control group (p = 0.07). At the final follow-up, mean visual acuity (SD) was 0.86 (0.21) for the former group and 0.78 (0.18) for the latter group, ath the difference was significant (p = 0.006). No side effects from bromfenac 0.09% were noted in patients of the bromfenac group over the course of the study.

Conclusion: The use of Broksinak containing bromfenac 0.09% as an additional therapy to complex treatment regimens improves the efficacy of treatment of HLA-B27-associated anterior uveitis. With the prolonged use of Broksinak, the bromfenac group exhibited a reduction in recurrence severity not less than the group treated with dexamethasone eye drops 0.1%. Moreover, the side effects (cataract and elevated IOP) typical for dexamethasone were seen significantly less frequently, and no corneal lesions were detected in the former group.


Balasubramaniam B, Chong YJ, Azzopardi M, Logeswaran A, Denniston AK. Topical Anti-Inflammatory Agents for Non-Infectious Uveitis: Current Treatment and Perspectives. J Inflamm Res. 2022; 15: 6439-6451.

Becker MD, Adamus G, Davey MP, Rosenbaum JT. The role of T cells in autoimmune uveitis. Ocul Immunol Inflamm. 2000;8:93-100. PMID: 10980681.;1-0;FT093

Wakefield D, Chang H John, Amjadi Shahriar, Maconochie Zoe, el-Asrar Ahmed Abu. McCluskey P. What is new HLA-B27 acute anterior uveitis? Ocul Immunol Inflamm. 2011 Apr;19(2):139-44.

Bouzid N, Jamilloux Y, Chapurlat R, Pradat P, De Parisot A, Kodjikian L, Sèves P. Impact of systemic treatments on the course of HLA-B27-associated uveitis: A retrospective study of 101 patients. PLoS One. 2020;15(3): e0230560.

Zborovskaia AV, Dorokhova AE. Biological therapy in treatment of uveitis. Contemporary trends. J Ophthalmol. (Ukraine). 2017;5:60-65.

Castiblanco С, Foster CS. Review of Systemic Immunosuppression for Autoimmune Uveitis. Ophthalmol Ther. 2014;3(1,2):17-36.

García-Lagunar MH, Gutiérrez-Cívicos MR, García-Simón MS, Conesa-Zamora P, Jimenez-Santos E, Cano-Vivar P, et al. Reasons for discontinuation and adverse effects of TNFα inhibitors in a cohort of patients with rheumatoid arthritis and ankylosing spondylitis. Ann Pharmacother. 2017;51(5):388-393.

Sampaio-Barros PD, van der Horst-Bruinsma IE. Adverse effects of TNF inhibitors in SpA: are they different from RA? Best Pract Res Clin Rheumatol. 2014 Oct;28(5):747-763. Epub 2014 Oct 31.

Taylor SR, Isa H, Joshi L, et al. New developments in corticosteroid therapy for uveitis. Ophthalmologica. 2010;224 Suppl 1:46-53.

Ferreira LB, Farrall AL, Furtado JM, Smith JR. Treatment of noninfectious uveitis. Arq Bras Oftalmol. 2021;84(6):610-21.

Fujishima H. Pharmacology, clinical efficacy and safety of bromfenac ophthalmic solution. Expert Rev Ophthalmol. 2007;2(4):543-549.

Tallouzi MO, Moore DJ, Bucknall N, et al. Outcomes important to patients with non-infectious posterior segment-involving uveitis: a qualitative study. BMJ Open Ophthalmol. 2020;5(1):e000481.

Airody A, Heath G, Lightman S, Gale R. Non-infectious uveitis: optimising the therapeutic response. Drugs. 2016;76(1):27-39.

Phulke S, Kaushik S, Kaur S, Pandav SS. Steroid-induced glaucoma: an avoidable irreversible blindness. J Curr Glaucoma Pract. 2017;11(2):67.

Raizman M. Corticosteroid therapy of eye disease: fifty years later. Arch Ophthalmol. 1996;114(8):1000-1001.

Pleyer U, Ursell PG, Rama P. Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same? Ophthalmol Ther. 2013;2(2):55-72.

Blum-Hareuveni T, Seguin-Greenstein S, Kramer M, et al. Risk factors for the development of cataract in children with uveitis. Am J Ophthalmol. 2017;177:139-143.

Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology.2010;117(7):1436-1441.

Petrushkin H, Rogers D, Pavesio C. The use of topical non-steroidal anti-inflammatory drugs for uveitic cystoid macular edema. Ocul Immunol Inflamm. 2018;26(5):795-797.

Wakai A, Lawrenson JG, Lawrenson AL, Wang Y, Brown MD, Quirke M, et al. Topical non-steroidal anti-inflammatory drugs for analgesia in traumatic corneal abrasions. Cochrane Database Syst Rev. 2017 May 18; 5:CD009781.

Asai T, Nakagami T, Mochizuki M, Hata N, Tsuchiya T, Hotta Y. Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug. Cornea. 2006;25:224-227.

Isawi H, Dhaliwal DK. Corneal melting and perforation in Stevens Johnson syndrome following topical bromfenac use. J Cataract Refract Surg. 2007;33:1644-1646.

Seitz B, Sorken K, LaBree LD, Garbus JJ, McDonnell PJ. Corneal sensitivity and burning sensation. Comparing topical ketorolac and diclofenac. Arch Ophthalmol. 1996;114:921-924.

Szerenyi K, Sorken K, Garbus JJ, Lee M, McDonnell PJ. Decrease in normal human corneal sensitivity with topical diclofenac sodium. Am J Ophthalmol. 1994;118:312-315.

Yanai K, Huang J, Kazuaki K, Eiichi U. Corneal sensitivity after topical bromfenac sodium eye-drop instillation. Clin Ophthalmol. 2013;7:741-744.

Radwan AE, Arcinue CA, Yang P, Artornsombudh P, Abu Al-Fadl EM, Foster CS. Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251(7):1801-1806.

Jones J, Francis P. Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent. Expert Opin Pharmacother. 2009;10(14):2379-2385.

Bucolo C, Drago F, Maisto R, Romano GL, D'Agata V, Maugeri G, Giunta S. Curcumin prevents high glucose damage in retinal pigment epithelial cells through ERK1/2-mediated activation of the Nrf2/HO-1 pathway. J Cell Physiol. 2019;234:17295-17304.



How to Cite

Zborovska O. Use of bromfenac 0.09% (Broksinak) in the complex therapy for HLA-B27-associated anterior uveitis. J.ophthalmol. (Ukraine) [Internet]. 2024 May 1 [cited 2024 May 29];(2):19-24. Available from:



Clinical Ophthalmology

Most read articles by the same author(s)